Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Goodwill (2019 - 2025)

Vivos Therapeutics has reported Goodwill over the past 7 years, most recently at $8.6 million for Q4 2025.

  • Quarterly Goodwill rose 207.14% to $8.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.6 million through Dec 2025, up 207.14% year-over-year, with the annual reading at $8.6 million for FY2025, 207.14% up from the prior year.
  • Goodwill was $8.6 million for Q4 2025 at Vivos Therapeutics, up from $8.5 million in the prior quarter.
  • Over five years, Goodwill peaked at $8.6 million in Q4 2025 and troughed at $2.7 million in Q1 2021.
  • The 5-year median for Goodwill is $2.8 million (2021), against an average of $3.7 million.
  • Year-over-year, Goodwill decreased 1.51% in 2022 and then skyrocketed 207.14% in 2025.
  • A 5-year view of Goodwill shows it stood at $2.8 million in 2021, then dropped by 1.51% to $2.8 million in 2022, then changed by 0.0% to $2.8 million in 2023, then changed by 0.0% to $2.8 million in 2024, then skyrocketed by 207.14% to $8.6 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Goodwill are $8.6 million (Q4 2025), $8.5 million (Q3 2025), and $8.4 million (Q2 2025).